Related Experiment Video
Updated: Jun 18, 2026
11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
O-GlcNAcylation regulates hyperglycemia-induced GPX1 activation
Won Ho Yang1, Sang Yoon Park, Suena Ji
1Department of Biology, Yonsei University, Seoul 120-749, Republic of Korea.
Biochemical and Biophysical Research Communications
|December 1, 2009
Summary
Hyperglycemia activates the antioxidant enzyme glutathione peroxidase 1 (GPX1) through O-linked N-acetylglucosamine (O-GlcNAc) modification. This O-GlcNAc modification is key for GPX1 activation and its interaction with kinases, impacting diabetes mellitus.
Area of Science:
- Biochemistry
- Cellular Biology
- Endocrinology
Background:
- Hyperglycemia, a hallmark of diabetes mellitus, triggers oxidative stress.
- Glutathione peroxidase 1 (GPX1) is a critical antioxidant enzyme involved in cellular defense against oxidative stress.
- The precise mechanism underlying GPX1 activation during hyperglycemia remains largely unknown.
Purpose of the Study:
- To elucidate the mechanism of GPX1 activation in response to hyperglycemia.
- To investigate the role of protein glycosylation, specifically O-linked N-acetylglucosamine (O-GlcNAc) modification, in GPX1 activation.
- To explore the therapeutic potential of targeting O-GlcNAc modification for managing hyperglycemia-related complications.
Main Methods:
- Utilized cell culture models to study hyperglycemia-induced changes in GPX1.
- Employed biochemical assays to detect O-GlcNAc modification on GPX1.
- Investigated the interaction between GPX1, c-Abl, and Arg kinases using co-immunoprecipitation.
- Administered O-GlcNAcase inhibitor (NTZ) in a mouse model to assess in vivo effects.
Main Results:
- Hyperglycemia induces O-GlcNAc modification of GPX1 on its C-terminus.
- O-GlcNAc modification is essential for GPX1 activation and its subsequent binding to c-Abl and Arg kinases.
- Pharmacological inhibition of O-GlcNAcase with NTZ successfully activated GPX1 in mouse liver tissue.
- GPX1 activation and O-GlcNAc modification are significantly implicated in hyperglycemia and diabetes mellitus.
Conclusions:
- Hyperglycemia-induced O-GlcNAc modification is a critical regulatory mechanism for GPX1 activation.
- GPX1 and its O-GlcNAc modification represent a novel therapeutic target for diabetes mellitus and associated oxidative stress.
- Targeting O-GlcNAcase offers a potential strategy to enhance antioxidant defenses in hyperglycemic conditions.
Related Concept Videos
01:09GPCRs Regulate Adenylyl Cylase Activity
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Two...
01:25cAMP-dependent Protein Kinase Pathways
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:58Cell Specific Gene Expression
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...